Limits...
Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.

Manolakopoulos S, Kranidioti H, Goulis J, Vlachogiannakos J, Elefsiniotis J, Kouroumalis EA, Koskinas J, Kontos G, Evangelidou E, Doumba P, Sinakos E, Vafiadou Ι, Koulentaki M, Papatheodoridis G, Akriviadis E - Ann Gastroenterol (2015 Oct-Dec)

Bottom Line: Ten patients (40%) stopped the therapy because of futility rules and 3 (12%) due to adverse events.There were no deaths, while two patients were hospitalized due to side effects.The triple therapy with BOC+pIFN+RBV in this cohort of real-life treatment-experienced CHC G1 patients and advanced liver disease was safe offering cure in the majority of those who could tolerate and complete treatment under a close monitoring.

View Article: PubMed Central - PubMed

Affiliation: 2 Department of Internal Medicine, General Hospital of Athens "Hippocratio" (Spilios Manolakopoulos, Hariklia Kranidioti, John Koskinas, George Kontos, Polyxeni Doumba).

ABSTRACT

Background: The aim of our study was to evaluate the safety and efficacy of triple therapy using boceprevir (BOC) with pegylated interferon (pIFN)/ribavirin (RBV) in chronic hepatitis C (CHC) genotype 1 (G1) treatment-experienced patients with advanced fibrosis or compensated cirrhosis.

Methods: We report the Greek experience on the first CHC patients who received BOC-based regimen. From September 2011 to June 2012, 26 treatment-experienced CHC patients and G1 with bridging fibrosis or compensated cirrhosis received 48 weeks of BOC+pIFN+RBV antiviral therapy. Data on complete blood counts and HCV RNA levels were obtained prior to therapy, at treatment weeks 4, 8, 12, 24, 36, 48 and 24 weeks after the end of treatment.

Results: A full set analysis was performed in 25 of 26 patients. Nine patients (36%) achieved sustained viral response (SVR). Ten patients (40%) stopped the therapy because of futility rules and 3 (12%) due to adverse events. Four patients (16%) developed a virological breakthrough (3 of those presented futility rules as well) and 2 (8%) relapse. All patients who achieved SVR had G 1b, 6 (67%) were non-cirrhotic and 5 (55%) had >1 log decline in baseline HCV RNA levels at week 4 of the treatment. There were no deaths, while two patients were hospitalized due to side effects.

Conclusion: The triple therapy with BOC+pIFN+RBV in this cohort of real-life treatment-experienced CHC G1 patients and advanced liver disease was safe offering cure in the majority of those who could tolerate and complete treatment under a close monitoring.

No MeSH data available.


Related in: MedlinePlus

Fluctation of mean neutrophils’ count during treatment. The highest decrease of neutrophils (mean drop 494 ± 336 / mm3) was observed at week 24
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4585396&req=5

Figure 4: Fluctation of mean neutrophils’ count during treatment. The highest decrease of neutrophils (mean drop 494 ± 336 / mm3) was observed at week 24

Mentions: Sixteen patients (64%) presented with neutropenia (<1500/mm3). Three (12%) patients had grade 4 neutropenia, 4 (16%) grade 3, 3 (12%) grade 2 and 6 (24%) grade 1. The highest decrease in neutrophils (mean 494±336/mm3) was observed at week 24. Growth CSF was administered in 2 (8%) patients and peg-IFNa dose was reduced in 6 (24%) patients (median duration 11 weeks, range 2-28) (Fig. 4). Two patients (8%) developed thrombocytopenia (<100,000/mm3) and one (4%) had <75,000 platelets/mm3. None of the patients developed bleeding events.


Boceprevir for chronic HCV genotype 1 infection in treatment-experienced patients with severe fibrosis or cirrhosis: The Greek real-life experience.

Manolakopoulos S, Kranidioti H, Goulis J, Vlachogiannakos J, Elefsiniotis J, Kouroumalis EA, Koskinas J, Kontos G, Evangelidou E, Doumba P, Sinakos E, Vafiadou Ι, Koulentaki M, Papatheodoridis G, Akriviadis E - Ann Gastroenterol (2015 Oct-Dec)

Fluctation of mean neutrophils’ count during treatment. The highest decrease of neutrophils (mean drop 494 ± 336 / mm3) was observed at week 24
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4585396&req=5

Figure 4: Fluctation of mean neutrophils’ count during treatment. The highest decrease of neutrophils (mean drop 494 ± 336 / mm3) was observed at week 24
Mentions: Sixteen patients (64%) presented with neutropenia (<1500/mm3). Three (12%) patients had grade 4 neutropenia, 4 (16%) grade 3, 3 (12%) grade 2 and 6 (24%) grade 1. The highest decrease in neutrophils (mean 494±336/mm3) was observed at week 24. Growth CSF was administered in 2 (8%) patients and peg-IFNa dose was reduced in 6 (24%) patients (median duration 11 weeks, range 2-28) (Fig. 4). Two patients (8%) developed thrombocytopenia (<100,000/mm3) and one (4%) had <75,000 platelets/mm3. None of the patients developed bleeding events.

Bottom Line: Ten patients (40%) stopped the therapy because of futility rules and 3 (12%) due to adverse events.There were no deaths, while two patients were hospitalized due to side effects.The triple therapy with BOC+pIFN+RBV in this cohort of real-life treatment-experienced CHC G1 patients and advanced liver disease was safe offering cure in the majority of those who could tolerate and complete treatment under a close monitoring.

View Article: PubMed Central - PubMed

Affiliation: 2 Department of Internal Medicine, General Hospital of Athens "Hippocratio" (Spilios Manolakopoulos, Hariklia Kranidioti, John Koskinas, George Kontos, Polyxeni Doumba).

ABSTRACT

Background: The aim of our study was to evaluate the safety and efficacy of triple therapy using boceprevir (BOC) with pegylated interferon (pIFN)/ribavirin (RBV) in chronic hepatitis C (CHC) genotype 1 (G1) treatment-experienced patients with advanced fibrosis or compensated cirrhosis.

Methods: We report the Greek experience on the first CHC patients who received BOC-based regimen. From September 2011 to June 2012, 26 treatment-experienced CHC patients and G1 with bridging fibrosis or compensated cirrhosis received 48 weeks of BOC+pIFN+RBV antiviral therapy. Data on complete blood counts and HCV RNA levels were obtained prior to therapy, at treatment weeks 4, 8, 12, 24, 36, 48 and 24 weeks after the end of treatment.

Results: A full set analysis was performed in 25 of 26 patients. Nine patients (36%) achieved sustained viral response (SVR). Ten patients (40%) stopped the therapy because of futility rules and 3 (12%) due to adverse events. Four patients (16%) developed a virological breakthrough (3 of those presented futility rules as well) and 2 (8%) relapse. All patients who achieved SVR had G 1b, 6 (67%) were non-cirrhotic and 5 (55%) had >1 log decline in baseline HCV RNA levels at week 4 of the treatment. There were no deaths, while two patients were hospitalized due to side effects.

Conclusion: The triple therapy with BOC+pIFN+RBV in this cohort of real-life treatment-experienced CHC G1 patients and advanced liver disease was safe offering cure in the majority of those who could tolerate and complete treatment under a close monitoring.

No MeSH data available.


Related in: MedlinePlus